滑膜病理类型与血清蛋白组模块整合决定早期类风湿关节炎疾病进展与治疗反应
该研究纳入两个独立队列共147例早期类风湿关节炎患者,评估滑膜病理类型及其相关血清蛋白组模式与6个月临床结局的关联。淋巴髓系病理类型与更高疾病活动度、自身抗体阳性及滑膜免疫浸润相关,其相关血清蛋白模式在组织学组间分布不同,但治疗分层关联仅为探索性且未达统计学显著。
要点
- 淋巴髓系滑膜病理类型与早期RA更高疾病活动度和自身抗体阳性相关
- Krenn评分高与炎症负荷和疾病活动度相关,但与治疗反应无显著差异
- 滑膜病理类型相关血清蛋白模式或可成为微创生物标志物候选
核心结论
- 早期RA滑膜病理类型与反映组织水平异质性的 distinct 循环蛋白组模式相关。
- 组织到血液的方法支持将病理类型相关血清谱开发为候选微创生物标志物。
- 该框架为RA精准医学提供了有前景的方向。
研究设计与样本
- 研究纳入两个独立队列共147例早期RA患者。
- 队列1中25例接受滑膜活检进行组织学分类和Krenn滑膜炎评分,活检时血清用Olink炎症面板分析。
- 队列2包含122例患者,用于评估预设血清蛋白组评分与6个月EULAR反应关联的方向一致性。
主要发现
- 淋巴髓系病理类型与更高疾病活动度、自身抗体阳性及滑膜免疫浸润增加相关。
- 高Krenn评分与更大炎症负荷和更高疾病活动度相关,但按Krenn评分治疗反应无显著差异。
- 滑膜病理类型与b/tsDMARD启用差异及探索性6个月反应模式相关。
- 队列1中病理类型相关血清蛋白模式在组织学组间分布不同。
- 淋巴髓系评分较高见于csDMARD应答者,弥漫髓系评分较高见于b/tsDMARD无应答者,该治疗分层关联为探索性,队列2调整后方向一致但均未达统计学显著。
关键数值与推荐
- 滑膜病理类型按组织学分类,Krenn滑膜炎评分用于评估滑膜炎症。
- 血清蛋白组用Olink炎症面板分析。
- 6个月结局采用EULAR反应标准评估。
临床怎么用
- 滑膜病理类型及Krenn评分可用于评估早期RA炎症负荷和疾病活动度。
- 病理类型相关血清蛋白模式有望作为微创生物标志物指导治疗分层,但目前仅为探索性,尚不能用于临床决策。
局限性
- 治疗分层关联为探索性,队列2调整后未达统计学显著。
- 队列1滑膜活检样本量较小(25例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis (RA) is characterised by marked clinical, histological and molecular heterogeneity, complicating treatment-response prediction. This study evaluated associations between synovial pathotypes, pathotype-associated serum proteomic patterns and 6-month clinical outcomes in early RA. METHODS: A total of 147 patients with early RA were included in two independent cohorts. In cohort 1, 25 patients underwent synovial biopsy for histological classification by synovial pathotype and Krenn synovitis score. Serum samples collected at biopsy were analysed using the Olink Inflammation panel. Cohort 2, comprising 122 patients, was used to assess the directional consistency of associations between predefined serum proteomic scores and 6-month European Alliance of Associations for Rheumatology (EULAR) response. RESULTS: The lymphomyeloid pathotype was associated with higher disease activity, autoantibody positivity and increased synovial immune infiltration. High Krenn score was also associated with greater inflammatory burden and higher disease activity. However, no significant differences in treatment response were observed according to Krenn score, whereas synovial pathotype was associated with differences in biological or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) initiation and exploratory 6-month response patterns. Pathotype-associated serum protein patterns identified in cohort 1 showed differential distributions across histological groups. Higher lymphomyeloid scores were observed among conventional synthetic disease-modifying antirheumatic drug responders, whereas higher diffuse-myeloid scores were observed among b/tsDMARD non-responders. These treatment-stratified associations were exploratory and directionally consistent after adjustment in cohort 2, although neither reached statistical significance. CONCLUSION: Synovial pathotypes in early RA were associated with distinct circulating proteomic patterns reflecting tissue-level heterogeneity. This tissue-to-blood approach supports development of pathotype-associated serum profiles as candidate minimally invasive biomarkers and provides a promising framework for precision medicine in RA.
引用
- Corrales S, Osuna-Soto J, Cid-Chaves A, et al. Integration of synovial pathotypes and serum proteomic modules as determinants of disease progression and therapeutic response in early rheumatoid arthritis. RMD Open. 2026. PMID: 42618211. doi:10.1136/rmdopen-2026-007196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。